Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Phase 1

Completed

Conditions: Breast Cancer
Bone Metastases

Interventions: Drug: Dasatinib
Drug: Zoledronic Acid

First Posted Date: 2007-12-03

Last Posted Date: 2022-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00566618

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Erlotinib
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2007-11-26

Last Posted Date: 2019-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT00563784

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Oral Valganciclovir Versus Valacyclovir

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Valacyclovir
Drug: Valganciclovir

First Posted Date: 2007-11-22

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00562770

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Drug: Decitabine
Drug: Interferon Alfa-2b

First Posted Date: 2007-11-21

Last Posted Date: 2011-12-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00561912

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Quality of Life Study for Prostate Cancer Patients

Conditions: Prostate Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-11-21

Last Posted Date: 2020-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1051

Registration Number: NCT00561444

Locations: 🇺🇸
MD Anderson at Cooper, Voorhees, New Jersey, United States
🇺🇸
MD Anderson Cancer Center at Albuquerque, Albuquerque, New Mexico, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Procedure: Endobronchial Ultrasound
Procedure: Mediastinoscopy

First Posted Date: 2007-11-16

Last Posted Date: 2018-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00559611

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Haelan and Nutrition in Cancer Patients

Phase 2

Terminated

Conditions: Cachexia
Weight Loss
Anorexia

Interventions: Drug: Haelan

First Posted Date: 2007-11-15

Last Posted Date: 2016-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00558558

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Role of Methadone As Co-Opioid Analgesic

Phase 2

Terminated

Conditions: Pain

Interventions: Drug: Morphine
Drug: Methadone

First Posted Date: 2007-11-15

Last Posted Date: 2016-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00558870

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Meditation and Cognitive Function in Women With Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Tibetan Meditation Program
Behavioral: No Meditation

First Posted Date: 2007-11-09

Last Posted Date: 2022-08-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT00556218

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Phase 1

Terminated

Conditions: Glioblastoma Multiforme
Anaplastic Glioma

Interventions: Procedure: Surgical Resection
Drug: Vorinostat
Drug: Isotretinoin
Drug: Temozolomide

First Posted Date: 2007-11-08

Last Posted Date: 2024-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00555399

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy